Addex Therapeutics EBITDA vs. Total Debt

ADXN Stock  USD 7.53  0.58  7.15%   
Based on Addex Therapeutics' profitability indicators, Addex Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Addex Therapeutics' ability to earn profits and add value for shareholders.
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
-10.2 M
Current Value
-10.7 M
Quarterly Volatility
8.5 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
As of the 24th of November 2024, Price To Sales Ratio is likely to drop to 2.01. In addition to that, Days Sales Outstanding is likely to drop to 32.43. At this time, Addex Therapeutics' Accumulated Other Comprehensive Income is very stable compared to the past year. As of the 24th of November 2024, Interest Income is likely to grow to about 65.8 K, while Operating Income is likely to drop (10.8 M).
For Addex Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Addex Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Addex Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Addex Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Addex Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Addex Therapeutics. If investors know Addex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Addex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(18.94)
Revenue Per Share
1.2
Quarterly Revenue Growth
(0.82)
Return On Assets
(0.62)
Return On Equity
(1.26)
The market value of Addex Therapeutics is measured differently than its book value, which is the value of Addex that is recorded on the company's balance sheet. Investors also form their own opinion of Addex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Addex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Addex Therapeutics' market value can be influenced by many factors that don't directly affect Addex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Addex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Addex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Addex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Addex Therapeutics Total Debt vs. EBITDA Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Addex Therapeutics's current stock value. Our valuation model uses many indicators to compare Addex Therapeutics value to that of its competitors to determine the firm's financial worth.
Addex Therapeutics is rated below average in ebitda category among its peers. It is rated below average in total debt category among its peers . Addex Therapeutics reported last year EBITDA of (10.23 Million). The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Addex Therapeutics' earnings, one of the primary drivers of an investment's value.

Addex Total Debt vs. EBITDA

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Addex Therapeutics

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(10.23 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Addex Therapeutics

Total Debt

 = 

Bonds

+

Notes

 = 
344.34 K
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

Addex Total Debt vs Competition

Addex Therapeutics is rated below average in total debt category among its peers. Total debt of Health Care industry is presently estimated at about 103.25 Million. Addex Therapeutics adds roughly 344,336 in total debt claiming only tiny portion of equities under Health Care industry.
Total debt  Workforce  Capitalization  Revenue  Valuation

Addex Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Addex Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Addex Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Addex Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Addex Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income29.8 M31.3 M
Operating Income-10.3 M-10.8 M
Income Before Tax-10.6 M-11.1 M
Total Other Income Expense Net-274.9 K-261.2 K
Net Loss-10.6 M-11.1 M
Income Tax Expense21.6 K20.5 K
Net Loss-10.6 M-11.1 M
Net Loss-18.7 M-17.8 M
Interest Income64 K65.8 K
Net Interest Income42.4 K44.5 K
Change To Netincome4.5 M4.7 M
Net Loss(0.14)(0.15)
Income Quality 0.76  0.84 
Net Income Per E B T 0.91  0.81 

Addex Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Addex Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Addex Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Addex Therapeutics' important profitability drivers and their relationship over time.

Use Addex Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Addex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Addex Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Addex Therapeutics Pair Trading

Addex Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Addex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Addex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Addex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Addex Therapeutics to buy it.
The correlation of Addex Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Addex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Addex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Addex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Addex Therapeutics position

In addition to having Addex Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Tips ETFs Thematic Idea Now

Tips ETFs
Tips ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Tips ETFs theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tips ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Addex Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Addex Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Addex Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Addex Therapeutics Stock:
Check out Trending Equities.
To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
To fully project Addex Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Addex Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Addex Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Addex Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Addex Therapeutics investors may work on each financial statement separately, they are all related. The changes in Addex Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Addex Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.